Acute Spinal Cord Injury Related Antibodies

Spinal cord injury (SCI) can be divided into primary and secondary injuries based on the mechanism of injury. The former is caused by the initial external force acting directly or indirectly on the spinal cord, while the latter is based on a series of physiological and biochemical mechanisms, such as oxidative stress, inflammatory response and excessive release of excitatory amino acids, which cause the intact tissue around the lesion to undergo self-destructive lesions, further deepening the degree of injury and expanding the area of injury.

Key Factors of SCI

• Inflammasome
  The inflammatory response is the major pathological process in the secondary injury phase. In the acute phase, reducing secondary injury by inhibiting neuroinflammation is believed to reduce damage to nerve function and achieve neuroprotection. A class of protein complexes known as inflammasome is primarily scaffolded by pattern recognition receptors from the PHYIN and NLR families as well as other receptor proteins. Some examples of common inflammasomes are AIM2, NLRP1, NLRP3, and NLRC4 (IPAF).

Immune Response
Immune response is a key pathological mechanism of SCI and determines the prognosis of the disease. When SCI occurs, local microglial reactions and the breakdown of the blood-spinal barrier allow blood-borne immune cells to enter the spinal cord. These cells release proinflammatory or immunomodulatory substances and contribute to the immune response. The immune response has always been thought to be harmful and detrimental to the repair of SCI. In the pathophysiology of SCI, all brain functioning cells exhibit pathogenic reactions, and neural cells and inflammatory cells communicate improperly. Understanding the pathogenic mechanism of SCI and identifying important regulatory targets will be aided by analyzing the response and communication mechanisms of these essential functional cells.

Fig.1 Schematic illustrating cellular changes following SCI¹.

At Creative Biolabs, our objective is to assist our clients in acquiring the most recent antibodies required for SCI research. Should you require further information regarding SCI-related antibodies, we invite you to explore the related products below or to contact us directly. We will respond to your inquiry in a timely manner.

Reference

1. Hu, Xiao, et al. "Spinal cord injury: molecular mechanisms and therapeutic interventions." Signal transduction and targeted therapy 8.1 (2023): 245.